

3. PROSPECTUS SUMMARY

This Prospectus Summary only highlights the key information from other parts of this Prospectus. It does not contain all the information that may be important to you. You should read and understand the contents of the whole Prospectus prior to deciding on whether to invest in our Shares.

3.1 PRINCIPAL DETAILS OF OUR IPO

3.1.1 Institutional Offering

The Institutional Offering involves the offering of up to 3,765,100,400 IPO Shares (comprising 3,319,716,600 Offer Shares and 445,383,800 Issue Shares), representing up to approximately 22.4% of our Enlarged Issued Shares, subject to the clawback and reallocation provisions and the Over-allotment Option as set out in Sections 4.2.4 and 4.2.5 of this Prospectus, at the Institutional Price in the following manner:

- (i) 2,100,866,800 Offer Shares, representing approximately 12.5% of our Enlarged Issued Shares to Bumiputera investors approved by the MITI; and
- (ii) up to 1,664,233,600 IPO Shares, representing approximately 9.9% of our Enlarged Issued Shares to the following persons:
 - (a) Malaysian institutional and selected investors (other than Bumiputera investors approved by the MITI);
 - (b) foreign institutional and selected investors outside the United States in reliance on Regulation S; and
 - (c) QIBs in the United States in reliance on Rule 144A or pursuant to applicable exemption from registration under the U.S. Securities Act.

3.1.2 Retail Offering

The Retail Offering involves the offering of 615,488,600 IPO Shares (comprising 539,773,900 Offer Shares and 75,714,700 Issue Shares), representing approximately 3.7% of our Enlarged Issued Shares, subject to the clawback and reallocation provisions as set out in Section 4.2.4 of this Prospectus, at the Retail Price to be allocated in the following manner:

- (i) **Allocation to the Eligible Persons**
279,350,000 IPO Shares, representing approximately 1.7% of our Enlarged Issued Shares, are reserved for application by the Eligible Persons.
- (ii) **Allocation via balloting to the Malaysian Public**
336,138,600 Offer Shares, representing 2.0% of our Enlarged Issued Shares, are reserved for application by the Malaysian Public, of which 168,069,300 Offer Shares have been set aside for application by Bumiputera citizens, companies, co-operatives, societies and institutions.

3. PROSPECTUS SUMMARY *(Cont'd)*

3.1.3 ESS

In conjunction with our Listing, we have established an ESS pursuant to which the ESGS Shares, the ESIS Shares and the ESOS Options may be granted to the eligible Executive Directors of our Company and employees of our Group (excluding dormant subsidiaries). The ESS shall be administered by our NRC in such manner as conferred upon it by our Board and governed by the ESS By-Laws. The maximum number of Shares which may be made available under the ESS shall not exceed, in aggregate, five percent (5.0%) of the total number of issued Shares (excluding treasury shares, if any) at any point of time during the duration of the ESS. The ESS shall be in force for a period of six (6) years from the effective date of the ESS and may be extended for a period of up to another four (4) years immediately from the expiry of the first six (6) years, provided that the aggregate duration of the ESS shall not exceed 10 years from its effective date.

3.1.4 Moratorium on our Shares

In accordance with the Equity Guidelines, HSG is not allowed to sell, transfer or assign any part of its holding in our Shares as at the date of our Listing, for a period of six (6) months from the date of our Listing. For detailed information relating to our IPO and moratorium on our Shares, see Sections 4.2 and 2.2 of this Prospectus, respectively.

3.1.5 Basis of arriving at the price of our IPO Shares

The Retail Price was determined and agreed upon by our Directors and the Selling Shareholder, in consultation with the Joint Lead Global Coordinators and Joint Global Coordinators, after taking into consideration, among others, our Group's strong financial performance, market-leading growth, competitive positioning and expansion plans.

Based on our Group's EBITDA of RM899.5 million and PATAMI of RM344.4 million for the FYE 31 March 2026, our EV/EBITDA multiple and PE multiple are approximately [●] times and [●] times, respectively. See Section 4.4.1 of this Prospectus for further details in relation to the basis of arriving at the price of our IPO Shares.

3.1.6 Expected market capitalisation

Based on the Retail Price and our Enlarged Issued Shares, the market capitalisation of our Company upon our Listing is approximately RM[●].

3.2 HISTORY AND BUSINESS

Our Company was incorporated in Malaysia under the Act 1965 on 23 March 1994 as a private limited company under the name of Asia Pacific Healthcare Corporation Sdn Bhd and is deemed registered under the Act 2016. Our Company subsequently changed its name to Columbia Pacific Healthcare Sdn Bhd on 4 October 1995, Columbia Asia Healthcare Sdn Bhd on 22 October 2007 and Asia OneHealthcare Sdn Bhd on 31 May 2024. On 22 September 2026, our Company was converted into a public company. The principal activities of our Company are investment holding and provision of management services to hospitals and other healthcare facilities. Our subsidiaries are principally involved in the operation of hospitals and other healthcare facilities, the provision of healthcare related services, and the provision of management services and information technology services.

3. PROSPECTUS SUMMARY (Cont'd)

We operate a differentiated multi-brand, multi-format portfolio with a primary focus in Malaysia. Our portfolio enables us to deliver care to patients across different market segments and demographics: (i) Subang Jaya Medical Centre, a quaternary hospital, as the pinnacle of our clinical network; (ii) tertiary hospitals with speciality focus (ALTY Orthopaedic Hospital, Beacon Hospital, Cardiac Vascular Sentral Kuala Lumpur, Hospital Picaso and Northern Heart Hospital Penang), providing focused centres of excellence in one (1) or more specific clinical disciplines; (iii) a network of secondary/tertiary hospitals (comprising Ara Damansara Medical Centre, Bukit Tinggi Medical Centre, ParkCity Medical Centre and the Columbia Asia network of hospitals); and (iv) recovery and rehabilitation facilities (comprising Columbia Asia Extended Care Hospital Shah Alam and TAGS). As at the LPD, we operate 23 hospitals (comprising 22 in Malaysia and one (1) in Vietnam) with a total licensed bed count of 2,632 (comprising 2,539 licensed beds in Malaysia and 93 licensed beds in Vietnam) and total built bed capacity of 3,057 (comprising 2,951 built bed capacity for Malaysia and 106 built bed capacity for Vietnam), and a network of recovery and rehabilitation facilities, and had 1,400 consultant specialists across our network facilities, including 750 resident consultant specialists (46 of whom were our employees) and 776 visiting consultant specialists.

See Sections 6 and 7 of this Prospectus for further details on our history, group structure and business.


3.3 COMPETITIVE STRENGTHS



For further details on our competitive strengths, see Section 7.4 of this Prospectus.

3. PROSPECTUS SUMMARY (Cont'd)

3.4 BUSINESS STRATEGY AND FUTURE PLANS



For further details on our business strategy and future plans, see Section 7.5 of this Prospectus.

3.5 RISK FACTORS

An investment in our Shares involves a number of risks, many of which are beyond our control. You should carefully consider all of the information contained in this Prospectus, including all the risk factors, before deciding to invest in our Shares. Set out below are the key risks faced by us in our business operations:

- (i) we are highly dependent on our doctors, nursing staff and other healthcare professionals. Our performance and the execution of our business strategy depend substantially on our ability to attract and retain leading doctors, nursing staff and other healthcare professionals. If we fail to recruit and retain these skilled personnel, our business, financial condition, results of operations, cash flows and prospects could be materially and adversely affected;
- (ii) our revenue is dependent on the demand from individual patients and corporate clients for private healthcare services. Our primary source of revenue is from inpatient care. Sustaining or growing inpatient income is closely tied to maintaining high occupancy rates at our hospitals and the case mix of our patients. Any decline in demand for our services could have a material adverse effect on our business, financial condition, results of operations and prospects;
- (iii) we depend heavily on our relationships with private insurance companies, who represent a significant portion of our payor base. Any inability to renew or maintain our contracts with such private insurance companies on favourable terms or at all, or failing to be on their panels of hospitals for cashless payments, could lead to significantly reduced patient demand and materially affect our business, financial condition and results of operations;
- (iv) the success of our business is dependent on our reputation and brand strength of our hospitals and hospital groups. Any adverse impact on the perception or value of these brands or our reputation may materially and adversely affect our business, financial condition, results of operations and prospects;

3. PROSPECTUS SUMMARY (Cont'd)

- (v) the integration of newly acquired hospitals and healthcare businesses with our existing operations is subject to inherent complexities, where anticipated synergies and operational benefits may not be fully realised. If we are unable to manage the growth of our business or are unable to successfully integrate newly acquired hospitals and healthcare businesses, our ability to compete effectively could be impaired, which may have a material adverse effect on our business, financial condition, results of operations and prospects;
- (vi) we may not be able to implement our strategies to grow our business which would limit our growth prospects. Our present growth strategies depend on our ability to ramp up operations at our existing facilities, enhance our clinical capabilities and strengthen our presence in both local and international markets. Our ability to successfully implement these strategies is subject to various risks, some of which may be beyond our control;
- (vii) pricing regulations and other related government reforms in the healthcare industry and the associated uncertainties could adversely affect our business, financial condition and results of operations. The healthcare industry in Malaysia is subject to extensive government regulation and the pricing of pharmaceutical products and medical services, as well as trade margins, are under active review. Governmental initiatives may impose new compliance obligations, increase operational costs and necessitate adjustments to our pricing and service models;
- (viii) our business operations and properties are subject to various laws, regulations and regulatory requirements, including land use, licensing and compliance certification requirements in Malaysia and Vietnam. We are required to obtain, maintain and, where applicable, regularly renew the requisite licences, approvals, permits and certifications and comply with the applicable regulatory requirements in respect of our business operations and properties; and
- (ix) the private healthcare business is highly competitive. Any failure to compete effectively could adversely affect our business, financial condition and results of operations.

For further details on our risk factors, see Section 5 of this Prospectus.

3.6 NON-COMPLIANCES WITH RELEVANT LAWS, REGULATIONS, RULES AND REQUIREMENTS GOVERNING THE CONDUCT OF THE OPERATIONS OF OUR GROUP

As at the LPD, our Group has certain outstanding non-compliances with the relevant laws, regulations, rules and requirements governing the conduct of operations of our hospitals and other facilities in Malaysia, including non-compliances and lapses relating to land use, licensing and compliance certification requirements. For further details of these non-compliances, see Section 7.25 of this Prospectus. The estimated cost of rectification in respect of the outstanding non-compliances is approximately RM2.5 million, while the potential maximum penalties which may be imposed in respect of such non-compliances amount to RM0.9 million. Accordingly, the total estimated cost of rectification and potential maximum penalties is approximately RM3.4 million, representing approximately 0.6% of our Group's PBT of RM508.8 million for the FYE 31 March 2026.

Notwithstanding that the outstanding non-compliances may remain unresolved at the time of our Listing, we will continue to engage with the relevant authorities/parties even after our Listing to resolve and address the outstanding non-compliances in accordance with the directions of the relevant authorities/parties. Our management is following up closely and liaising with relevant authorities/parties to resolve the said non-compliances in the best interest of our Company. The impact of the outstanding non-compliances, individually and collectively, is not material to the business operations and financial condition of our Group.

3. PROSPECTUS SUMMARY (Cont'd)**3.7 DIRECTORS AND KEY SENIOR MANAGEMENT**

As at the date of this Prospectus, our Directors and Key Senior Management are as follows:

Name	Designation
<u>Directors</u>	
Tan Sri Quek Leng Chan	Chairman and Non-Independent Non-Executive Director
Ganendran Sarvananthan	Non-Independent Non-Executive Director
Stephen John Watson Hagger	Senior Independent Non-Executive Director
Dr. Chan Boon Kheng	Managing Director and Group CEO
Dr. Chong Su-Lin	Independent Non-Executive Director
Lim Tau Kien	Independent Non-Executive Director
Zaida Khalida binti Shaari	Independent Non-Executive Director
Quek Kon Sean	Alternate Director to Tan Sri Quek Leng Chan
<u>Key Senior Management</u>	
Dr. Chan Boon Kheng	Managing Director and Group CEO
Anwar Anis	Group Chief Commercial Officer and Executive Director of A1H Super-specialty Centres
Poorani Ramachandran	Group CFO

For further information on our Directors and Key Senior Management, see Sections 9.2.1 and 9.3.1 of this Prospectus, respectively.

(The rest of this page is intentionally left blank)

3. PROSPECTUS SUMMARY (Cont'd)

3.8 PROMOTER AND SUBSTANTIAL SHAREHOLDERS

The following tables set out the direct and indirect shareholding of our Promoter and substantial shareholders before and after our IPO:

Name/ Nationality or Country of incorporation	Before our IPO				After the issuance of new A1H Shares pursuant to the HHHPL Partial Exchange			
	Direct		Indirect		Direct		Indirect	
	No. of Shares	(1)%	No. of Shares	(1)%	No. of Shares	(2)%	No. of Shares	(2)%
Promoter and substantial shareholder								
HSG/ Singapore	16,273,585,398	100.0	-	-	16,273,585,398	99.9	-	-
Substantial shareholders								
HLT/ Cayman Islands	-	-	16,273,585,398	(5)100.0	-	-	16,273,585,398	(5)99.9
HLHG/ Malaysia	-	-	16,273,585,398	(6)100.0	-	-	16,273,585,398	(6)99.9
HLCM/ Malaysia	-	-	16,273,585,398	(7)100.0	-	-	16,273,585,398	(7)99.9
HL Holdings/ Malaysia	-	-	16,273,585,398	(8)100.0	-	-	16,273,585,398	(8)99.9
TSQLC/ Malaysian	-	-	16,273,585,398	(9)100.0	-	-	16,273,585,398	(9)99.9
HLIH/ Singapore	-	-	16,273,585,398	(8)(10)100.0	-	-	16,273,585,398	(8)(10)99.9
Hong Realty/ Singapore	-	-	16,273,585,398	(8)100.0	-	-	16,273,585,398	(8)99.9
Davos/ Singapore	-	-	16,273,585,398	(11)100.0	-	-	16,273,585,398	(11)99.9
Kwek Leng Kee/ Singaporean	-	-	16,273,585,398	(12)100.0	-	-	16,273,585,398	(12)99.9
Kwek Holdings/ Singapore	-	-	16,273,585,398	(11)100.0	-	-	16,273,585,398	(11)99.9
Kwek Leng Beng/ Singaporean	-	-	16,273,585,398	(13)100.0	-	-	16,273,585,398	(13)99.9
Calico/ Cayman Islands	-	-	16,273,585,398	(6)100.0	-	-	16,273,585,398	(6)99.9
OHA 1/ Cayman Islands	-	-	16,273,585,398	(14)100.0	-	-	16,273,585,398	(14)99.9
OHA 2/ Cayman Islands	-	-	16,273,585,398	(15)100.0	-	-	16,273,585,398	(15)99.9
OHH/ Cayman Islands	-	-	16,273,585,398	(16)100.0	-	-	16,273,585,398	(16)99.9
TPG Asia VIII/ Singapore	-	-	16,273,585,398	(17)100.0	-	-	16,273,585,398	(17)99.9
TPG Asia VIII Fund/ Cayman Islands	-	-	16,273,585,398	(18)100.0	-	-	16,273,585,398	(18)99.9

3. PROSPECTUS SUMMARY (Cont'd)

Name/ Nationality or Country of incorporation	After our IPO and assuming the Over-allotment Option is not exercised				After our IPO and assuming the Over-allotment Option is fully exercised ⁽⁴⁾			
	Direct		Indirect		Direct		Indirect	
	No. of Shares	⁽³⁾ %	No. of Shares	⁽³⁾ %	No. of Shares	⁽³⁾ %	No. of Shares	⁽³⁾ %
Promoter and substantial shareholder								
HSG/ Singapore	12,414,094,898	73.9	-	-	11,757,006,598	70.0	-	-
Substantial shareholders								
HLT/ Cayman Islands	-	-	12,414,094,898	⁽⁵⁾ 73.9	-	-	11,757,006,598	⁽⁵⁾ 70.0
HLHG/ Malaysia	-	-	12,414,094,898	⁽⁶⁾ 73.9	-	-	11,757,006,598	⁽⁶⁾ 70.0
HLCM/ Malaysia	-	-	12,414,094,898	⁽⁷⁾ 73.9	-	-	11,757,006,598	⁽⁷⁾ 70.0
HL Holdings/ Malaysia	-	-	12,414,094,898	⁽⁸⁾ 73.9	-	-	11,757,006,598	⁽⁸⁾ 70.0
TSQLC/ Malaysian	-	-	12,414,094,898	⁽⁹⁾ 73.9	-	-	11,757,006,598	⁽⁹⁾ 70.0
HLIH/ Singapore	-	-	12,414,094,898	⁽⁸⁾⁽¹⁰⁾ 73.9	-	-	11,757,006,598	⁽⁸⁾⁽¹⁰⁾ 70.0
Hong Realty/ Singapore	-	-	12,414,094,898	⁽⁸⁾ 73.9	-	-	11,757,006,598	⁽⁸⁾ 70.0
Davos/ Singapore	-	-	12,414,094,898	⁽¹¹⁾ 73.9	-	-	11,757,006,598	⁽¹¹⁾ 70.0
Kwek Leng Kee/ Singaporean	-	-	12,414,094,898	⁽¹²⁾ 73.9	-	-	11,757,006,598	⁽¹²⁾ 70.0
Kwek Holdings/ Singapore	-	-	12,414,094,898	⁽¹¹⁾ 73.9	-	-	11,757,006,598	⁽¹¹⁾ 70.0
Kwek Leng Beng/ Singaporean	-	-	12,414,094,898	⁽¹³⁾ 73.9	-	-	11,757,006,598	⁽¹³⁾ 70.0
Calico/ Cayman Islands	-	-	12,414,094,898	⁽⁶⁾ 73.9	-	-	11,757,006,598	⁽⁶⁾ 70.0
OHA 1/ Cayman Islands	-	-	12,414,094,898	⁽¹⁴⁾ 73.9	-	-	11,757,006,598	⁽¹⁴⁾ 70.0
OHA 2/ Cayman Islands	-	-	12,414,094,898	⁽¹⁵⁾ 73.9	-	-	11,757,006,598	⁽¹⁵⁾ 70.0
OHH/ Cayman Islands	-	-	12,414,094,898	⁽¹⁶⁾ 73.9	-	-	11,757,006,598	⁽¹⁶⁾ 70.0
TPG Asia VIII/ Singapore	-	-	12,414,094,898	⁽¹⁷⁾ 73.9	-	-	11,757,006,598	⁽¹⁷⁾ 70.0
TPG Asia VIII Fund/ Cayman Islands	-	-	12,414,094,898	⁽¹⁸⁾ 73.9	-	-	11,757,006,598	⁽¹⁸⁾ 70.0

Notes:

(1) Based on our enlarged issued Shares of 16,273,585,398 after the Share Split.

(2) Based on our enlarged issued Shares of 16,285,835,972 after the HHHPL Partial Exchange.

(3) Based on our Enlarged Issued Shares.

(4) Assuming an Over-allotment Option of up to 657,088,300 Shares, representing approximately 15.0% of the total number of our IPO Shares offered is fully exercised.

(5) Deemed interested by virtue of its shareholding in HSG, applying Section 8(4) of the Act 2016.

(6) Deemed interested by virtue of its shareholding in HLT, applying Section 8(4) of the Act 2016.

(7) Deemed interested by virtue of its shareholding in HLHG, applying Section 8(4) of the Act 2016.

(8) Deemed interested by virtue of its shareholding in HLCM, applying Section 8(4) of the Act 2016.

(9) Deemed interested by virtue of his shareholding in HL Holdings, applying Section 8(4) of the Act 2016.

(10) Deemed interested by virtue of his shareholding in Hong Realty, applying Section 8(4) of the Act 2016.

(11) Deemed interested by virtue of its shareholding in HLIH, applying Section 8(4) of the Act 2016.

(12) Deemed interested by virtue of his shareholding in Davos, applying Section 8(4) of the Act 2016.

3. PROSPECTUS SUMMARY (Cont'd)

- (13) Deemed interested by virtue of his shareholding in Kwek Holdings, applying Section 8(4) of the Act 2016.
- (14) Deemed interested by virtue of its shareholding in Calico, applying Section 8(4) of the Act 2016
- (15) Deemed interested by virtue of its shareholding in OHA 1, applying Section 8(4) of the Act 2016.
- (16) Deemed interested by virtue of its shareholding in OHA 2, applying Section 8(4) of the Act 2016.
- (17) Deemed interested by virtue of its interest in OHH, applying Section 8(4) of the Act 2016.
- (18) Deemed interested by virtue of its shareholding in TPG Asia VIII, applying Section 8(4) of the Act 2016.

For further details on our Promoter and substantial shareholders, see Section 9.1 of this Prospectus.

3.9 DIVIDEND POLICY

In conjunction with our Listing, we have adopted a dividend policy that reflects our priority of reinvesting in our growth pipeline, while providing shareholders with a return on their investment. We target a dividend payout ratio of up to 30.0% of our consolidated PATAMI for each financial year, after taking into account the working capital, maintenance capital and committed capital requirements.

The declaration and payment of any dividend is subject to the approval of our Board, which will take into account, among other factors, our Group's capital expenditure requirements and expansion plans, financial performance and working capital requirements, and gearing levels, as well as any applicable law, licence conditions and contractual obligations, and provided that such distribution will not be detrimental to our Group's cash requirements, or any plans approved by our Board. This statement reflects our Board's present intention only and does not constitute a profit forecast or a legally binding commitment as to future dividend declarations.

3.10 FINANCIAL AND OPERATIONAL HIGHLIGHTS

	FYE 31 March		
	2024	2025	2026
	RM'000	RM'000	RM'000
Revenue	1,437,905	2,899,780	3,293,670
GP	748,716	1,401,231	1,550,553
PBT	270,534	55,926	508,828
Tax expense	(83,787)	(149,422)	(155,329)
Profit/(Loss) for the year	186,747	(93,496)	353,499
PATAMI/(LATAMI)	186,840	(85,846)	344,368
GP margin (%) ⁽¹⁾	52.1	48.3	47.1
PBT margin (%) ⁽²⁾	18.8	1.9	15.4
PATAMI/(LATAMI) margin (%) ⁽³⁾	13.0	(3.0)	10.5
Effective tax rate (%) ⁽⁴⁾	31.0	267.2	30.5
Basic and diluted EPS/(LPS) (sen) ⁽⁵⁾	7.11	(1.17)	4.23
Net cash from operating activities	381,432	708,675	818,218
Net cash used in investing activities	(4,903,466)	(347,288)	(389,095)
Net cash from/(used in) financing activities	4,646,005	(477,284)	(333,926)

Notes:

- (1) Computed based on GP divided by revenue.
- (2) Computed based on PBT divided by revenue.
- (3) Computed based on PATAMI/(LATAMI) divided by revenue.
- (4) Computed based on tax expense divided by PBT.
- (5) Computed based on PATAMI/(LATAMI) divided by the weighted average number of Shares in issue during the respective financial year.

3. PROSPECTUS SUMMARY (Cont'd)

	As at 31 March		
	2024	2025	2026
	RM'000	RM'000	RM'000
Total assets	7,791,261	10,799,209	11,039,316
Total liabilities	2,773,361	3,340,465	3,283,788
Total equity	5,017,900	7,458,744	7,755,528
Total debts ⁽¹⁾	1,987,941	2,251,188	2,158,742
Adjusted net debt ⁽²⁾	1,434,836	1,810,218	1,514,029
Gross gearing ratio (times) ⁽³⁾	0.4	0.3	0.3
Adjusted net gearing ratio (times) ⁽⁴⁾	0.3	0.2	0.2

Notes:

- (1) Computed based on total loans and other borrowings plus MTN Programme and lease liabilities.
(2) Computed based on total debts less cash and cash equivalents and other investments (excluding pledged deposits). See Section 12.1 of this Prospectus for a reconciliation to total debts.
(3) Computed based on total debts over total equity as at the end of the financial year.
(4) Computed based on adjusted net debt over total equity as at the end of the financial year.

	As at 31 March or for the FYE 31 March		
	2024	2025	2026
Licensed bed count	2,130	2,392	2,571
<u>Inpatient</u>			
Operating beds (as at year end)	1,943	2,164	2,301
Operating beds (weighted average)	1,336	2,120	2,223
Occupancy rate (%)	69.2	67.7	65.3
Inpatient admissions	141,349	227,042	233,106
Inpatient days	338,597	524,099	530,176
Average length of stay	2.4	2.3	2.3
Average revenue per inpatient admission (RM)	7,540	9,023	10,039
<u>Outpatient</u>			
Outpatient visits	1,225,994	2,154,759	2,200,345
Average revenue per outpatient visit (RM)	256	352	393

For further details on our financial and operational highlights, see Section 12 and Section 7.6 of this Prospectus.

3.11 USE OF PROCEEDS

We expect to use the gross proceeds from our Public Issue amounting to approximately RM[●] million⁽¹⁾ in the following manner:

Description of use of proceeds	Estimated timeframe for use from the date of our Listing	Amount (RM'000)	%
Expansion Capex	Within 36 months	[●]	[●]
Maintenance Capex	Within 36 months	[●]	[●]
Repayment of bank borrowings	Within 12 months	[●]	[●]
Defray fees and expenses relating to our IPO and Listing	Within 12 months	[●]	[●]
Total		[●]	[●]

Note:

- (1) We have assumed that the Institutional Price and the Final Retail Price will be equal to the Retail Price.

For detailed information relating to the use of proceeds arising from our Public Issue, see Section 4.6 of this Prospectus.